Company Overview

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RAR? agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

Recent Press Releases

March 20, 2017Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

March 1, 2017Syros to Present New Data on Lead Drug Candidates, SY-1425 and SY-1365, and CDK12/13 Inhibitor Program at Upcoming AACR Annual Meeting

March 1, 2017Syros Pharmaceuticals to Present at Upcoming Investor Conferences

February 27, 2017Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference

Upcoming Events

There are currently no events scheduled.

NASDAQ: SYRS0.00$15.00Volume: 0Today's Open: $0.00Previous Close: $15.00
Data as of 03/28/17 4:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.

IR Contact

Hannah Deresiewicz
Stern Investor Relations

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Syros Pharmaceuticals Inc posts new information to the site. Just enter your e-mail address and click Submit.